<DOC>
	<DOCNO>NCT01707381</DOCNO>
	<brief_summary>This clinical investigation perform compare effect BOL-303259-X dose daily ( QD ) timolol maleate 0.5 % dosed twice daily ( BID ) reduce intraocular pressure ( IOP ) measure 24-hour period subject open-angle glaucoma ( OAG ) ocular hypertension ( OHT ) .</brief_summary>
	<brief_title>BOL-303259-X With Timolol 0.5 % Subjects With Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Subjects must diagnosis OAG OHT 1 eye . Subjects treatmentnaïve must meet follow IOP requirement Visit 1 ( Screening ) , pretreated subject must meet follow IOP requirement Visit 2 ( Washout ) : Intraocular pressure ≥ 22 mmHg least 1 eye ≤ 36 mmHg eye . Subjects expose BOL303259X within 3 month prior Visit 1 ( Screening ) . Subjects history presence chronic generalize systemic disease Investigator feel might increase risk subject confound result study . Subjects irregular daily sleep schedule . Subjects unable wear sleep monitoring device 7 day prior laboratory study . Subjects anticipate need initiate modify medication ( systemic topical ) know affect IOP . Subjects concomitant use medication may interact safety efficacy nitric oxide . Subjects know hypersensitivity contraindication latanoprost ingredient study drug . Subjects expect require treatment ocular systemic corticosteroid . Subjects need topical systemic treatment OAG OHT . Subjects unable discontinue contact lens use 24 hour laboratory study . Subjects central corneal thickness great 600 μm either eye . Subjects condition prevents reliable applanationtonometry either eye . Subjects advance glaucoma subject cup/disc ratio great 0.8 history split fixation , field loss threaten fixation either eye . Subjects previous active corneal disease . Subjects history severe dry eye . Subjects active optic disc hemorrhage . Subjects history central/branch retinal vein artery occlusion . Subjects history macular edema . Subjects narrow angle subject angle closure , congenital , secondary glaucoma , subject history angle closure either eye . Subjects diagnosis clinically significant progressive retinal disease either eye . Subjects intraocular infection inflammation within 3 month prior Visit 1 ( Screening ) . Subjects history ocular laser surgery within 3 month prior Visit 1 ( Screening ) . Subjects history incisional ocular surgery severe trauma within 3 month prior Visit 1 ( Screening ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>